Physician profile
Cooper Michael Clark
NPI 1255598488
$13,183.16
in general payments reported to CMS, 2019-2025
16 companies · $700 in 2025
The $700 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,137 · 2020: $238 · 2021: $1,018 · 2022: $3,275 · 2023: $315 · 2024: $500 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,514.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $7,606.27 | 2019-2021 | |
| Abbvie INC. | $3,080.02 | 2022-2025 | Ozurdex |
| Notal Vision, INC. | $410.80 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $386.16 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $375.16 | 2021-2025 | Vabysmo |
| Alimera Sciences, INC. | $277.16 | 2019-2024 | Iluvien, Yutiq |
| Alcon Vision LLC | $249.58 | 2019-2025 | Clareon |
| Astellas Pharma US INC | $205.48 | 2023-2025 | Izervay |
| Rxsight INC | $143.51 | 2022 | |
| Novartis Pharmaceuticals Corporation | $138.39 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $133.12 | 2020-2021 | |
| Apellis Pharmaceuticals, INC. | $51.25 | 2023-2024 | Syfovre |
| Sun Pharmaceutical Industries INC. | $40.96 | 2019 | |
| Ani Pharmaceuticals, INC. | $32.94 | 2025 | Iluvien |
| Bausch & Lomb Americas INC. | $31.45 | 2022-2024 | Xiidra, Miebo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $20.91 | 2024 | Byooviz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cooper Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.